A Phase 2/3 interventional study of Inhaled Treprostinil in Pulmonary Hypertension, Interstitial Lung Disease and Combined Pulmonary Fibrosis and Emphysema, sponsored by United Therapeutics. Terminated at 92 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-02.
Sponsored by United Therapeutics · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 7th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2016, is one of 2 in phase 2/3, and was the 21st registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:
Valley Health System · Sites in United States
Ages 18+
Liquidia Technologies, Inc. · Sites in United States, Australia, Austria and 9 more countries
Ages 18–80
Magdi H. Yacoub · Sites in Egypt
Ages 18+
University of California, San Diego
Ages 18+
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 163 Hypertension, Pulmonary studies recruiting now, 99 (61%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 17 · Phase 4 9
First in 1998; this study’s year is marked. 3 started in 2016.
This study's enrollment of 243 is above the median of 35 across 649 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 32 across the 37 interventional studies. Of the 29 that completed or were terminated, 19 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 38 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
36 studies in Hypertension, Pulmonary by United Therapeutics: 4 open now, 4 under way, 2 of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 36 studies in Hypertension, Pulmonary by United Therapeutics, this one is the 9th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2016, is one of 3 in phase 2/3, and was the 19th registered.
United Therapeutics’s Hypertension, Pulmonary studies by the year they started, since 1998.
1 of the studies testing treprostinil in Hypertension, Pulmonary that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07116681University of California, San DiegoEffects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension | 2027-07-01 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among United Therapeutics’s 36 in Hypertension, Pulmonary:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 266 patients who completed all required assessments in the RIN-PH-201 study at approximately 100 clinical trial centers. The study will continue Your participation in this study is voluntary and will last until you discontinue from the study or the study ends. The study will continue until each subject reaches the Week 108 visit or until inhaled treprostinil become commercially available for patients with PH associated with ILD including CPFE (whichever is sooner).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females of must be non-pregnant (as confirmed by a urine pregnancy test at Baseline) and non-lactating, and will:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label access
Drug: Inhaled Treprostinil
Inhaled treprostinil up to 15 breaths (90 mcg) four times daily
Also known as: Tyvaso
Change in Peak 6-Minute Walk Distance (6MWD) From Baseline
The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living. Change in 6MWD from Baseline correlates with the current clinical standard for assessing patient functional status in the treatment of PH and is considered an objective measure of patient functional status. Subjects will be instructed to walk down a corridor at a comfortable speed as far as they can manage for 6 minutes. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation. Peak exposure 6MWD will occur by conducting 6MWT within 10 to 60 minutes after the most recent dose of study drug dose.
Time frame: Baseline through Week 124 in RIN-PH-202 (Combined data from parent study RIN-PH-201 [NCT02630316] and this open-label extension study RIN-PH-202)
Change in Plasma Concentration of N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) From Baseline
The N-terminal pro-BNP (NT-proBNP) serum concentration is a useful biomarker associated with changes in right heart morphology and function. NT-proBNP serum concentration will be assessed to compare the severity of heart failure at Baseline and each visit through Week 124. Blood for NT-proBNP assessment must be drawn prior to conducting the 6-minute walk test (6MWT).
Time frame: Baseline through Week 124 in RIN-PH-202 (Combined data from parent study RIN-PH-201 [NCT02630316] and this open-label extension study RIN-PH-202)
Change in Percent Predicted Forced Vital Capacity (FVC) From Baseline
Change in pulmonary function following inhaled treprostinil therapy will be measured by Forced Vital Capacity (FVC), calculated from a Pulmonary Function Test (PFT) performed at Baseline and Weeks 12, 48, and 108.
Time frame: Baseline and Weeks 12, 48, and 108
| Milestone | Inhaled Treprostinil |
|---|---|
| Started | 243 |
| Received inhaled treprostinil in rin-ph-202 (safety population) | 242 |
| Completed | 70 |
| Not completed | 173 |
| Withdrew: Death | 56 |
| Withdrew: Progressive disease | 12 |
| Withdrew: Adverse event | 29 |
| Withdrew: Withdrawal by subject | 41 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Study terminated by sponsor | 24 |
| Withdrew: Withdrawal by sponsor prior to dose administration | 1 |
| Withdrew: Lung transplant | 5 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Principal investigator terminated study site | 1 |
The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living. Change in 6MWD from Baseline correlates with the current clinical standard for assessing patient functional status in the treatment of PH and is considered an objective measure of patient functional status. Subjects will be instructed to walk down a corridor at a comfortable speed as far as they can manage for 6 minutes. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation. Peak exposure 6MWD will occur by conducting 6MWT within 10 to 60 minutes after the most recent dose of study drug dose.
| meters | Inhaled Treprostinil |
|---|---|
| Week 4 | 1.5 (-197 to 258) |
| Week 8 | 5.0 (-259 to 196) |
| Week 12 | 9.5 (-190 to 192) |
| Week 16 | 10.0 (-269 to 183) |
| Week 20 | 12.0 (-189 to 169) |
| Week 28 | 10.0 (-222 to 175) |
| Week 40 | 3.0 (-261 to 171) |
| Week 52 | 3.0 (-223 to 194) |
| Week 64 | -2.0 (-218 to 178) |
| Week 76 | -2.0 (-209 to 210) |
| Week 88 | -5.0 (-180 to 185) |
| Week 100 | -11.0 (-213 to 196) |
| Week 112 | -24.0 (-183 to 216) |
| Week 124 | -16.0 (-287 to 190) |
The N-terminal pro-BNP (NT-proBNP) serum concentration is a useful biomarker associated with changes in right heart morphology and function. NT-proBNP serum concentration will be assessed to compare the severity of heart failure at Baseline and each visit through Week 124. Blood for NT-proBNP assessment must be drawn prior to conducting the 6-minute walk test (6MWT).
| pg/mL | Inhaled Treprostinil |
|---|---|
| Week 8 | -5.10 (-9704.2 to 34,807.3) |
| Week 16 | -1.30 (-11,433.0 to 87,148.3) |
| Week 64 | 10.2 (-10,280.0 to 7306.0) |
| Week 124 | 31.90 (-4500.2 to 26,197.7) |
Change in pulmonary function following inhaled treprostinil therapy will be measured by Forced Vital Capacity (FVC), calculated from a Pulmonary Function Test (PFT) performed at Baseline and Weeks 12, 48, and 108.
| Percent Predicted FVC | Inhaled Treprostinil |
|---|---|
| Week 12 | 0.5 (-16 to 23) |
| Week 48 | 2.0 (-10 to 21) |
| Week 108 | 3.0 (-13 to 13) |
Collected over AEs were recorded throughout the course of the study from the time that each subject signed the ICF until all study assessments were completed, through the time that the study was terminated by the Sponsor (following the approval of inhaled treprostinil for use in patients with PH-ILD), up to 108 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inhaled Treprostinil | 56/242 (23.1%) | 133/242 (55%) | 229/242 (94.6%) |
| Event | Inhaled Treprostinil |
|---|---|
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 28/242 |
| PneumoniaInfections and infestations | 21/242 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 13/242 |
| Right ventricular failureCardiac disorders | 10/242 |
| Acute kidney injuryRenal and urinary disorders | 9/242 |
| Cardiac arrestCardiac disorders | 8/242 |
| Fluid overloadMetabolism and nutrition disorders | 8/242 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 8/242 |
| SepsisInfections and infestations | 7/242 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/242 |
| Event | Inhaled Treprostinil |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 65/242 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 63/242 |
| HeadacheNervous system disorders | 45/242 |
| DiarrhoeaGastrointestinal disorders | 37/242 |
| DizzinessNervous system disorders | 36/242 |
| Upper respiratory tract infectionInfections and infestations | 34/242 |
| NauseaGastrointestinal disorders | 32/242 |
| FatigueGeneral disorders | 32/242 |
| PneumoniaInfections and infestations | 30/242 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 30/242 |
Safety Population
| Age, Continuous(years) | Inhaled Treprostinil |
|---|---|
| Median | 70.0 (27 to 90) |
| Sex: Female, Male(Participants) | Inhaled Treprostinil |
|---|---|
| Female | 116 |
| Male | 126 |
| Ethnicity (NIH/OMB)(Participants) | Inhaled Treprostinil |
|---|---|
| Hispanic or Latino | 17 |
| Not Hispanic or Latino | 224 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Inhaled Treprostinil |
|---|---|
| American Indian or Alaska Native | 3 |
| Asian | 8 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 53 |
| White | 178 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Time Since Diagnosis(years) | Inhaled Treprostinil |
|---|---|
| Median | 0.51 (0.3 to 13.3) |
| Current Diagnosis(Participants) | Inhaled Treprostinil |
|---|---|
| Idiopathic interstitial pneumonia | 108 |
| Chronic hypersensitivity pneumonitis | 13 |
| Occupational lung disease | 5 |
| Combined pulmonary fibrosis and emphysema | 59 |
| Connective tissue disease | 57 |
| 6-Minute Walk Distance (6MWD)(meters) | Inhaled Treprostinil |
|---|---|
| Median | 270.0 (24 to 549) |
| N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)(pg/mL) | Inhaled Treprostinil |
|---|---|
| Median | 465.70 (10.2 to 92,852) |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Aug 2021, 58 months.
Results were first posted in Dec 2022, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil